A Colchicine Derivative in Therapy of Chronic Myelocytic Leukemia

Lessmann, Ellen M.

doi:10.1001/jama.1961.03040090001001

Cited by 11 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ro tational therapy has the theoretical advantage of pos sibly delaying the emergence of resistant clones or the appearance of cumulative drug toxicity. Hence it might be worthy of further study [5], Our experience with TMCA is similar to that of others [6] with another colchicine analog, demecolcin. That agent is no longer available in the USA.…”

Section: Discussionsupporting

confidence: 67%

Rotational Therapy with a Colchicine Analog in Chronic Granulocytic Leukemia

Stolinsky¹,

Weiner²,

Bateman³

1980

Oncology

View full text Add to dashboard Cite

9 patients with chronic granulocytic leukemia were treated sequentially with busulfan, 6-mercaptopurine, and trimethylcolchicinic acid methyl ether d-tartrate (TMCA; NSC-36354). Smoothness of control of the disease was similar with busulfan and 6-mercaptopurine, but it was significantly poorer with TMCA. Toxic effects of therapy and median survival were similar to those observed with conventional therapy.

show abstract

Section: Discussionsupporting

confidence: 67%

Rotational Therapy with a Colchicine Analog in Chronic Granulocytic Leukemia

Stolinsky¹,

Weiner²,

Bateman³

1980

Oncology

View full text Add to dashboard Cite

show abstract

Survival in chronic myelogenous leukemia: Influence of treatment and extent of disease at diagnosis

Monfardini¹,

Gee²,

Fried³

et al. 1973

Cancer

View full text Add to dashboard Cite

A retrospective study was conducted on the survival of 178 patients with chronic myelogenous leukemia from January 1948 through December 1967. Through analysis of survival time, comparison has been made between a group of 50 patients treated with chemotherapy alone vs. a group of 84 patients treated with radiation therapy to the spleen and chemotherapy. No difference could be found in these two major therapeutic groups (median survival 31 months for both). Further analysis has been made to determine whether survival could be correlated to the initial extent of disease. Initial hemoglobin value, WBC, platelet counts, absolute blast count, spleen size, and selected combination of these factors showed no significant correlation with survival. Acute blastic transformation occurred in 60% of 117 patients. Infection as a cause of death was less frequent in patients with progressive disease without acute blastic transformation, while renal failure due to hyperuricemia and thromboembolic phenomena occurred more often in this group as compared with patients dying in acute blastic phase.

show abstract